Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
Not provided
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Specific Aim 1: To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage.
Specific Aim 2: To compare the terminal bioburden of the wounds at the time of definitive closure or coverage as sampled by standard tissue microbiology.
Specific Aim 3: To compare rates of antibiotic-related serious adverse events (SAEs) of the two treatment groups.
Exploratory Aim 4: To pilot the use of available and emerging rapid PCR platforms for wound pathogen identification in a sub-cohort of patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. |
|
| Treatment | Experimental | The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard of care | Drug | Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. |
| Measure | Description | Time Frame |
|---|---|---|
| Deep surgical site infection | To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage. | 182 days from injury |
| Measure | Description | Time Frame |
|---|---|---|
| Deep surgical site infection | To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage. | 365 days from injury |
| Fracture revision rates |
Not provided
Inclusion Criteria:
Injury meeting at least one of the following criteria:
Ages 18 - 64 years inclusive
Patients may have risk factors for infection including diabetes, immunosuppression from steroids or other medications, HIV, or other infections.
Patients may have a traumatic brain injury.
Patients may have other fractures including spine, upper extremity fractures, contralateral lower extremity injuries, ipsilateral pelvis, hip, femur or foot injuries.
Patients may be treated initially at an outside institution prior to transfer to the study institution, as long as the definitive wound closure or coverage was not performed prior to entrance into the study.
Patients with bilateral injuries that meet inclusion criteria may be included, but only the limb rated as "more severe" by the treating surgeon will be enrolled in the study.
Patients may have co-existing non-tibial or hindfoot infection, with or without antibiotic treatment.
Patients may be definitively stabilized using any method (nail, plate, ex fix or cast).
Patients may have a fasciotomy.
Exclusion Criteria:
Patient in current therapy for a wound, implant or fracture site infection related to the study site.
Patient likely to have difficulty maintaining follow-up, including:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Suna Chung, MPH | Contact | 4105023357 | schung60@jhu.edu | |
| Susan C Collins, MSc | Contact | 410-502-8966 | scolli21@jhu.edu |
| Name | Affiliation | Role |
|---|---|---|
| Micahel J Bosse, MD | Carolinas Medical Center | Principal Investigator |
| Rachel Seymour, PhD | Atrium Health Musculoskeletal Institute Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Recruiting | Redwood City | California | 94063 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vancomycin and Tobramycin | Drug | The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden. |
|
Fracture revision rates for non-union, flap failure, amputation, the development of resistant bacteria discovered at revision surgery and antibiotic-related complications (C. difficile, nephrotoxicity, ototoxicity). |
| 365 days from injury |
| Renan C Castillo, PhD |
| Johns Hopkins Bloomberg School of Public Health |
| Principal Investigator |
| Anthony R Carlini, MS | Johns Hopkins Bloomberg School of Public Health | Principal Investigator |
| _University of California, San Francisco | Recruiting | San Francisco | California | 94110 | United States |
|
| University of California at San Francisco | Recruiting | San Francisco | California | 94110 | United States |
|
| University of Colorado Anschutz Medical Campus | Recruiting | Aurora | Colorado | 80045 | United States |
|
| St Mary's University/Tenent Health | Recruiting | West Palm Beach | Florida | 33407 | United States |
|
| Emory University School of Medicine | Recruiting | Atlanta | Georgia | 30303 | United States |
|
| Indiana University School of Medicine - Methodist Hospital | Recruiting | Indianapolis | Indiana | 46202 | United States |
|
| Indiana University/Eskenazi Health | Recruiting | Indianapolis | Indiana | 46202 | United States |
|
| University of Kentucky | Recruiting | Lexington | Kentucky | 40506 | United States |
|
| LSU Health Sciences | Recruiting | New Orleans | Louisiana | 70112 | United States |
|
| University of Maryland , MD Department of Orthopaedics | Recruiting | Baltimore | Maryland | 21201 | United States |
|
| Walter Reed Military Medical Center | Recruiting | Bethesda | Maryland | 20889 | United States |
|
| Harvard/Mass General/Brigham Hospitals | Recruiting | Boston | Massachusetts | 02115 | United States |
|
| Hennepin County Medical Center / Minneapolis | Recruiting | Minneapolis | Minnesota | 55415 | United States |
|
| University of Mississippi Medical Center | Recruiting | Jackson | Mississippi | 39216 | United States |
|
| Dartmouth Hitchcock | Recruiting | Lebanon | New Hampshire | 03766 | United States |
|
| Jamaica Hospital Medical Center | Recruiting | Jamaica | New York | 11418 | United States |
|
| University of North Carolina at Chapel Hill | Recruiting | Chapel Hill | North Carolina | 27514 | United States |
|
| Atrium Health Carolinas Medical Center | Recruiting | Charlotte | North Carolina | 28203 | United States |
|
| Atrium Health Wake Forest Baptist | Recruiting | Winston-Salem | North Carolina | 27157 | United States |
|
| METROHealth | Recruiting | Cleveland | Ohio | 44109 | United States |
|
| Ohio State University Wexner Medical Center | Recruiting | Columbus | Ohio | 43201 | United States |
|
| University of Oklahoma College of Medicine | Recruiting | Oklahoma City | Oklahoma | 73104 | United States |
|
| Temple University | Recruiting | Philadelphia | Pennsylvania | 19140 | United States |
|
| Brown University/Rhode Island Hospital | Recruiting | Providence | Rhode Island | 02905 | United States |
|
| Rhode Island Hospital/Brown University | Recruiting | Providence | Rhode Island | 02905 | United States |
|
| Vanderbilt University Medical Center | Recruiting | Nashville | Tennessee | 37232 | United States |
|
| University of Texas Health Science Center - Houston | Recruiting | Houston | Texas | 77030 | United States |
|
| University of Virginia | Recruiting | Charlottesville | Virginia | 22903 | United States |
|
| Inova Fairfax MEdical Campus | Recruiting | Falls Church | Virginia | 22042 | United States |
|
| Virginia Commonwealth University Medical Center | Recruiting | Richmond | Virginia | 23298 | United States |
|
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| D014640 | Vancomycin |
| D014031 | Tobramycin |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
| D006020 | Glycopeptides |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009328 | Nebramycin |
| D007612 | Kanamycin |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
Not provided
Not provided